Navigation Links
Panacea Biotech To Market Anthrax Vaccine

Panacea Biotech has bagged the registration, production and marketing rights of the anti-anthrax vaccine developed by the Centre for Biotechnology in the Jawaharlal Nehru University (JNU). It is expected that the vaccine would be in the market in 3-4 months. The Company has made a milestone payment to JNU for the exclusive rights. In addition, it will pay the university a royalty on sales. However, the company is yet to make any projections on the business the vaccine is expected to generate.//

The vaccine is different from drugs such as ciprofloxacin currently being used in the treatment of anthrax. Ciprofloxacin is administered after a person has contacted anthrax. The vaccine develops immunity in the human body to anthrax bacillus. According to marketing director Rajesh, the vaccine developed by JNU is superior to the only other anti-anthrax vaccine available in the US. The vaccine in the US has a lot of toxic side- effects. The side-effect profile of this (JNU) vaccine is negligible. As anthrax has become a national emergency, the government's policy of fast-track registration will come into effect. This, in turn, will lead to a speedy commercialisation of the vaccine.


'"/>




Page: 1

Related medicine news :

1. Panacea Biotec In-Licenses FMD Vaccine
2. Panacea To Market Measles Vaccine In India
3. Websites That Offer Panacea for Eating Disorders may Be Dangerous
4. Biotechnology industry expected to grow into a three billion dollar industry by 2002
5. Biotechnology on the lead
6. Commercialization of Biotech Discoveries, An Encouragement For Researchers
7. Biotech drug causing anemia-EPREX
8. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
9. Biologicals Transfer Proposal between US and Indian Biotechnology
10. Vical Biotech and NIH jointly develops HIV vaccine
11. Biotechnology Initiatives Planned In Hyderabad
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood associated ... appearing online in the journal Radiology. , Heart disease and brain disease exact a ... the rapidly aging population. Damage to both organs often occurs at a subclinical stage, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a worldwide ... US market its advanced highly customizable contact technology solutions. , ODU Single Contact ... technologies are ideal for a wide range of applications that require customization from ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... and financial planning services to families and business owners in the greater Dallas ... behalf of the Dallas Fallen Officer Foundation. , Established in 2009 by active ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Inc. (NASDAQ: IONS ), the leader in antisense therapeutics, ... BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December ... A live webcast of the presentation will be available on the ... be available within 48 hours and will be archived for a ... , , ...
(Date:12/7/2016)... Inc. (NYSE: LCI ) today announced that the company ... Healthcare Conference on December 14, 2016 at 9:20 a.m. (ET) at ... . In addition, the company will host one-on-one meetings ... Annual Boston Healthcare Conference taking place on December 13, 2016 at ... , ...
(Date:12/6/2016)... 2016  Alopexx Oncology, LLC announced data from a ... protein (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal ... B cells as Rituxan and maintains the activities of ... involved in tumor targeting, engagement of the immune system, ... of the study (abstract #95954) were presented at the ...
Breaking Medicine Technology: